Home > Health & Beauty > Clinical Trials

Clinical Trials

Mesothelioma Cancer Cardio AIDS
Alternative Medicine Biotechnology Clinical Trials
Dental Diabetes FDA
Fitness & Nutrition Genetics Hospitals
Infectious Diseases Medical Devices Medical Supplies
Mental Health Nursing Oncology
Optical Pharmaceutical Radiology
Veterinary
May 21, 2013 18:00
SAN FRANCISCO--(BUSINESS WIRE)--Otsuka Pharmaceutical Co., Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) today announced results from a preliminary analysis that showed statistically significant reductions (p<0.0001) in total psychiatric hospitalization rates in patients diagnosed with schizophren...
World  World      Clinical Trials  Clinical Trials
May 21, 2013 18:00
サンフランシスコ--(BUSINESS WIRE)--(ビジネスワイヤ) -- 大塚製薬株式会社(本社:東京都千代田区、代表取締役社長:岩本太郎、以下「大塚製薬」)とH.ルンドベックA/S (本社:デンマーク、コペンハーゲン、CEO:ウルフ・ウインバーグ、以下「ルンドベック社」) は、経口抗精神病薬から、アリピプラゾール持続性懸濁注射剤である月1回投与の「エビリファイ メンテナ」への切り替えが実施された統合失調症の患者さんでは、前治療の経口抗精神病薬と比較して、精神症状再発による入院率が有意に低下した(P<0.0001)結果*1を予備的な解析として得ましたのでお知らせします。統合失調症の...
World  World      Clinical Trials  Clinical Trials
May 21, 2013 17:59
SUNNYVALE, Calif.--(BUSINESS WIRE)--Elixir announces excellent 6 month safety, efficacy results for CE Marked, fully bioresorbable DESolve Scaffold System at Late Breaking Trials Session of EuroPCR. Increase in scaffold and lumen area.
World  World      Clinical Trials  Clinical Trials
May 21, 2013 17:52
ST. PAUL, Minn. & PARIS--(BUSINESS WIRE)--St. Jude Medical EnligHTNment is the largest randomized, prospective clinical trial to determine whether renal denervation offers additional health benefits beyond lowering blood pressure.
World  World      Clinical Trials  Clinical Trials
May 21, 2013 17:52
ST. PAUL, Minn. & PARIS--(BUSINESS WIRE)--St. Jude Medical, Inc. (NYSE:STJ), ein weltweit tätiges Medizintechnik-Unternehmen, gab heute den Start seiner wegweisenden klinischen Studie EnligHTNment bekannt. Dabei handelt es sich um die größte randomisierte Prospektivstudie zur Klärung der Frage, o...
World  World      Clinical Trials  Clinical Trials
May 21, 2013 17:25
ORLANDO, Fla.--(BUSINESS WIRE)--AstraZeneca (NYSE: AZN) today presented the results of two pivotal Phase III studies of naloxegol showing the 25 mg dose of the investigational drug met its primary and secondary endpoints for efficacy and showed a safety profile consistent with previous studies. D...
World  World      Clinical Trials  Clinical Trials